Cargando…

Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with EZH2 mutation in Japan

Tazemetostat is a selective, reversible, small‐molecule inhibitor of the histone methyltransferase enzyme, enhancer of zest homolog 2 (EZH2). In this multicenter, open‐label, phase II study, we assessed the efficacy and safety of tazemetostat in Japanese patients with relapsed or refractory (R/R) B‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Izutsu, Koji, Ando, Kiyoshi, Nishikori, Momoko, Shibayama, Hirohiko, Teshima, Takanori, Kuroda, Junya, Kato, Koji, Imaizumi, Yoshitaka, Nosaka, Kisato, Sakai, Rika, Hojo, Seiichiro, Nakanishi, Tadashi, Rai, Shinya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409398/ https://www.ncbi.nlm.nih.gov/pubmed/34159682 http://dx.doi.org/10.1111/cas.15040

Ejemplares similares

Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
por: Munakata, Wataru, et al.
Publicado: (2021)

Tazemetostat: EZH2 Inhibitor
por: Straining, Rachael, et al.
Publicado: (2022)

The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B‐cell lymphoma and enhances T‐cell recruitment
por: Yuan, Hepei, et al.
Publicado: (2021)

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft
por: Passeri, Thibault, et al.
Publicado: (2022)

Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study
por: Ohmachi, Ken, et al.
Publicado: (2018)

The role of tazemetostat in relapsed/refractory follicular lymphoma
por: von Keudell, Gottfried, et al.
Publicado: (2021)

Evaluation of Tazemetostat as a Therapeutically Relevant Substance in Biliary Tract Cancer
por: Bekric, Dino, et al.
Publicado: (2023)

Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study
por: Izutsu, Koji, et al.
Publicado: (2021)

Oral histone deacetylase inhibitor tucidinostat (HBI‐8000) in patients with relapsed or refractory adult T‐cell leukemia/lymphoma: Phase IIb results
por: Utsunomiya, Atae, et al.
Publicado: (2022)

Targeted Therapy for Relapsed/Refractory Follicular Lymphoma: Focus on Clinical Utility of Tazemetostat
por: Raychaudhuri, Ruben, et al.
Publicado: (2022)

Pharmacokinetics of Herb-Drug Interactions of Plumbagin and Tazemetostat in Rats by UPLC-MS/MS
por: Li, Heng, et al.
Publicado: (2022)

Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin’s lymphoma: an open-label, multicenter, dose-escalation phase 1 study
por: Goto, Hideki, et al.
Publicado: (2022)

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
por: Murayama, Kayoko, et al.
Publicado: (2022)

ATRT-17. TARGETING GLUTAMINE METABOLISM LOWERS METHYLATION POTENCIALS IN AT/RT AND SYNERGIZE WITH TAZEMETOSTAT
por: Nakata, Satoshi, et al.
Publicado: (2020)

Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma
por: Tansir, Ghazal, et al.
Publicado: (2021)

Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma
por: Maruyama, Dai, et al.
Publicado: (2020)

Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study
por: Iida, Shinsuke, et al.
Publicado: (2019)

Adult T‐cell leukemia‐lymphoma as a viral disease: Subtypes based on viral aspects
por: Nosaka, Kisato, et al.
Publicado: (2021)

Epidemiology of adult T‐cell leukemia‐lymphoma in Japan: An updated analysis, 2012‐2013
por: Ito, Shigeki, et al.
Publicado: (2021)

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma
por: Terui, Yasuhito, et al.
Publicado: (2021)

A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
por: Watanabe, Takashi, et al.
Publicado: (2016)

Continuous high-dose infusion of doripenem in a pneumonia patient infected by carbapenem-resistant Pseudomonas aeruginosa: a case report
por: Oda, Kazutaka, et al.
Publicado: (2019)

Outcomes in Patients with Classic Hodgkin Lymphoma Treated with ABVD: A Single-center Retrospective Study
por: Makiyama, Junya, et al.
Publicado: (2020)

Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
por: Goto, Hideki, et al.
Publicado: (2020)

Immunogenicity of recurrent mutations in MYD88 and EZH2 in non-Hodgkin lymphomas
por: Nielsen, Julie S, et al.
Publicado: (2015)

The outcome of watchful waiting in patients with previously treated follicular lymphoma
por: Fujino, Takahiro, et al.
Publicado: (2022)

Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study
por: Izutsu, Koji, et al.
Publicado: (2021)

DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study
por: Miyazaki, Kana, et al.
Publicado: (2019)

Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score–matched analysis of E7438-G000-101 trial outcomes
por: Proudman, David G., et al.
Publicado: (2022)

Integrase Interactor 1 (INI1) Deficiency in a Lung Cancer Patient Presents Nonresponse to Immunotherapy and Tazemetostat: A Case Report
por: Chen, Xiuxiu, et al.
Publicado: (2023)

S5-KL-1 CURRENT TREATMENT FOR DLBCL AND PROPHYLAXIS AND TREATMENT FOR SECONDARY CNS LYMPHOMA
por: Izutsu, Koji
Publicado: (2019)

Predictive impact of soluble interleukin‐2 receptor and number of extranodal sites for identification of patients at very high risk of CNS relapse in diffuse large B‐cell lymphoma
por: Shichijo, Takafumi, et al.
Publicado: (2022)

Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016)

Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma
por: Shibayama, Hirohiko, et al.
Publicado: (2019)

P1109: TRIAL IN PROGRESS: PHASE 1B/2 TRIAL OF TAZEMETOSTAT IN COMBINATION WITH VARIOUS TREATMENTS IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
por: Bessudo, A., et al.
Publicado: (2022)

Anti-CCR4 antibody activates virus specific immune response in STLV-1 infected Japanese monkey
por: Sugata, Kenji, et al.
Publicado: (2015)

Tazemetostat decreases β-catenin and CD13 protein expression in HEPG-2 and Hepatitis B virus-transfected HEPG-2 with decreased cell viability
por: Amin, Mohamed N., et al.
Publicado: (2023)

A multicenter, open‐label, phase II study of tirabrutinib (ONO/GS‐4059) in patients with Waldenström’s macroglobulinemia
por: Sekiguchi, Naohiro, et al.
Publicado: (2020)

Two‐year outcomes of tirabrutinib monotherapy in Waldenström’s macroglobulinemia
por: Sekiguchi, Naohiro, et al.
Publicado: (2022)

Clinical utility of genomic profiling of AML using paraffin‐embedded bone marrow clots: HM‐SCREEN‐Japan 01
por: Hosono, Naoko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fofrm4snenfo9h0fqs757flv58